Antibe Therapeutics (TSX:ATE) EV-to-EBIT : 2.15 (As of May. 13, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Antibe Therapeutics's Enterprise Value is C$-39.17 Mil. Antibe Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-18.23 Mil. Therefore, Antibe Therapeutics's EV-to-EBIT for today is 2.15.

The historical rank and industry rank for Antibe Therapeutics's EV-to-EBIT or its related term are showing as below:

TSX:ATE' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.61 Med: -4.01 Max: 2.53
Current: 2.15

During the past 12 years, the highest EV-to-EBIT of Antibe Therapeutics was 2.53. The lowest was -12.61. And the median was -4.01.

TSX:ATE's EV-to-EBIT is ranked better than
59.4% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs TSX:ATE: 2.15

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Antibe Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$24.07 Mil. Antibe Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-18.23 Mil. Antibe Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -75.75%.

Antibe Therapeutics EV-to-EBIT Historical Data

The historical data trend for Antibe Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics EV-to-EBIT Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

Get a 7-Day Free Trial

-5.34

-9.45

-6.75

0.54

0.38

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															0.83	0.38	0.52	0.11	-1.32

Competitive Comparison of Antibe Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Antibe Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's EV-to-EBIT falls into.

Antibe Therapeutics EV-to-EBIT Calculation

Antibe Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-39.169	/	-18.234
	=	2.15

Antibe Therapeutics's current Enterprise Value is C$-39.17 Mil.
Antibe Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-18.23 Mil.

Antibe Therapeutics (TSX:ATE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Antibe Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-18.234	/	24.072822
	=	-75.75 %

Antibe Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$24.07 Mil.
Antibe Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-18.23 Mil.

Antibe Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines